Sionna Therapeutics Inc
Follow $SION
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $SION by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is SION moving today?
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
SION overview
Related filings and maps
Congress activity in SION
No receipt-qualified Congressional disclosure is present for SION in the cached public ledger.
SION contract awards, year to date.
Public federal awards linked to this ticker.
SION lobbying filings, year to date.
Registered lobbying filings matched to Sionna Therapeutics Inc.